Correlate genotype and immunophenotype with measured ex vivo drug response to test enrichment hypotheses and draft a companion-diagnostic rationale grounded in real patient biology.
A biomarker that predicts function is more valuable than one that only describes biology. We link what is present (genotype, immunophenotype) to what happens (measured functional drug response) using the same primary-derived cells.
Genotype/phenotype-response correlation
Statistical association between markers and ex vivo response
Enrichment rules
Drug candidate inclusion criteria supported by relevant functional data
CDx rationale
Companion-diagnostic hypothesis generation
Integrated workflow
Combining flow immunophenotyping and targeted NGS with drug-response data in a single study
Functionally validated biomarkers sharpen inclusion criteria, reduce the number of patients needed to see a signal, and strengthen the translational narrative for protocols and partners.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
